KR20200083146A - Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid - Google Patents

Abstract

The present invention relates to a composition for preventing and treating muscle diseases or improving muscle functions, containing an Illicium verum extract and shikimic acid. The Illicium verum extract and shikimic acid according to the present invention have an effect of increasing activity of mTOR involved in muscle protein synthesis and reducing the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, thereby having an effect of eminently enhancing muscle functions. In addition, since the present invention is a natural product, the composition can be safely used without side effects, thereby being able to be used as a material for pharmaceuticals, foods or cosmetics.

Description

Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid

The present invention relates to a composition for the prevention and treatment of muscle diseases containing octagonal fennel or shikimic acid or for improving muscle function.

Muscle atrophy is caused by a gradual decrease in muscle mass and refers to muscle weakness and degeneration (Cell, 119(7): 907-910, 2004). Muscle atrophy is promoted by inactivity, oxidative stress, and chronic inflammation and weakens muscle function and motor capacity (Clinical Nutrition, 26(5): 524-534, 2007). The most important factor in determining muscle function is muscle mass, which is maintained by a balance of protein synthesis and degradation. Muscular dystrophy occurs when protein degradation occurs more than synthesis (The International Journal of Biochemistry and Cell Biology, 37(10): 1985-1996, 2005).

Muscle size is regulated by intracellular signaling pathways that induce anabolism or catabolism within the muscle, and when there are more signaling reactions that induce synthesis rather than degradation of muscle proteins Muscle protein synthesis is increased, which results in an increase in muscle size (hypertrophy) or an increase in muscle fiber number (hyperplasia) with muscle protein increase (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011).

Factors involved in muscle protein synthesis induce protein synthesis by phosphorylating downstream proteins starting from stimulation of the phosphatidylinositol-3 kinase (PI3K)/Akt pathway in muscle cells. The activity of mammalian target of rapamycin (mTOR) by PI3K/Akt signaling is recognized as a central growth signaling factor that integrates various growth signals in cells. mTOR contributes to muscle mass gain by inducing muscle protein synthesis by activating two factors that initiate mRNA translation, 4E-binding protein (4EBP1) and phosphorylated 70-kDa ribosomal S6 kinase (p70S6K) (The Korea Journal of Sports Science, 20(3): 1551-1561, 2011; The International Journal of Biochemistry and Cell Biology, 43(9): 1267-1276, 2011). Conversely, when the transcription factor forhead box (FoxO) moves from the cytoplasm into the nucleus, the expression of the E3 ubiquitin ligase factors atrogin-1 and MuRF-1, which are involved in protein degradation, increases (Disease Models and Mechanisms, 6: 25). -39, 2013). When these expression levels increase, protein breakdown in muscles is promoted, and muscle mass decreases. Therefore, promoting mTOR activity and suppressing atrogin-1 and MuRF-1 expression increases muscle protein and increases muscle mass.

Muscle cell differentiation and muscle formation are regulated by a variety of muscle regulatory factors. Among them, MyoD triggers the expression of muscle-specific genes and induces differentiation of muscle satellite cells into myoblasts. Induction of myogenin expression by the activity of MyoD is the most important factor in fusion of myoblasts and is involved in the formation of myotubes. The muscle fibers formed through this process form a bundle and finally form muscles (Cellular and Molecular Life Sciences, 70: 4117-4130, 2013).

The octagonal fennel ( Ilicium verum Hooker fil.) refers to the fruits of magnolia and evergreen, and eight pods wrapped in a hard shell are shaped like stars, and are generally called star anise. It is mainly used as a spice, mainly after drying and in powder form. Anti-cancer (Journal of Medicinal Plants Research, 4(24): 2666-2673. 2016), antioxidant (Food Chemistry, 104(1): 59-66, 2007), Anti-inflammatory activity (Journal of Ethnopharmacology, 144(1): 182-189, 2012) has been reported.

Shikimic acid is one of the components included in octagonal fennel, and is an important biochemical intermediate involved in the biosynthesis of alkaloids, flavonoids, and lignin, as well as amino acids. Sikkim acid is an antithrombotic (Journal of Natural Medicine, 70(3): 492-501, 2016), antibacterial (Bioengineered, 4(4): 244-248, 2013), neuroprotection (Journal of Molecular Neuroscience, 56(4) : 956-965, 2015), antiviral activity (Journal of Agricultural and Food Chemistry, 52(17): 5391-5395, 2004).

However, prior to the present invention, it was not known about the prevention and treatment of muscle diseases of octagonal or sickimic acid or improvement of muscle function.

It is an object of the present invention to provide a technique capable of preventing and treating muscle disease or improving muscle function by having protein expression inhibitory activity involved in muscle protein degradation and protein expression involved in muscle protein synthesis without side effects. .

However, the technical problem to be achieved by the present invention is not limited to the problems mentioned above, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.

As a means for solving the above problems, the present invention provides a muscle disease prevention, for the improvement or treatment compositions comprising octagonal anise (Illicium verum) extract or fractions thereof as an active ingredient.

In another aspect, the present invention provides a composition for preventing, improving or treating muscle diseases comprising shikimic acid represented by Formula 1 below or a salt thereof as an active ingredient:

[Formula 1]

Octagonal fennel (Illicium verum) according to the present invention extracts or Sikkim acid (shikimic acid) is a muscle protein p-mTOR protein expression increases relating to the synthesis, muscle MuRF-1 and inhibit mRNA expression of atrogin-1 which is involved in protein degradation It has an excellent effect. In addition, since the present invention is a natural product, it can be safely used without side effects, and thus can be used as a pharmaceutical, food, or cosmetic material.

Figure 1 shows the results of measuring the activity of mTOR according to the treatment of octagonal fennel hot water extract, octagonal 50% ethanol extract or octagonal ethanol extract in L6 muscle cells.
Figure 2 shows the results of measuring the protein expression level of p-mTOR, an mRNA translation-related biomarker, according to the treatment of octagonal hot water extract, octagonal 50% ethanol extract, or octagonal ethanol extract in L6 muscle cells.
Figure 3 shows the results of measuring the mRNA expression of atrogin-1 and MuRF-1 according to the treatment of octagonal hot water extract, octagonal 50% ethanol extract, or octagonal hot water extract in L6 muscle cells.
Figure 4 shows the results of measuring the activity of mTOR according to the treatment of the supercritical extract bar fennel 200bar, octagonal 400bar supercritical extract in L6 muscle cells.
Figure 5 shows the results of measuring the protein expression level of the biomarker p-mTOR related to mRNA translation according to the treatment of sikkim acid in L6 muscle cells.
Figure 6 shows the results of measuring the mRNA expression levels of atrogin-1 and MuRF1 according to the treatment of sikkim acid in L6 muscle cells.

Hereinafter, the present invention will be described in detail.

The present invention provides a octagonal fennel (Illicium verum) extracts or fractions muscle disorders or for the prevention and treatment of muscle function improving composition comprising as an active ingredient thereof.

In addition, the present invention provides a composition for preventing and treating muscle disease or improving muscle function, including shikimic acid or a salt thereof as an active ingredient.

The present inventors have tried to develop a natural substance that improves muscle function. As a result, the octagonal fennel extract or shikimic acid isolated therefrom has an effect of preventing or treating muscle disease by increasing the expression and activity of genes involved in muscle function. Clarified.

The composition of the present invention includes an octagonal fennel extract as an active ingredient.

The'octagonal fennel ( Illicium verum )' used in the composition of the present invention belongs to the family Illiciaceae, of course, including its subspecies and varieties. In addition, the octagonal fennel of the present invention is self-evident in the art and includes a classmate herbal medicine that can be used for the same or similar purposes as the prevention and treatment purposes of the present invention.

In the present specification,'extract' means that a substance is dissolved in a solvent to separate its active ingredient or characteristic ingredient. Specifically, the extract includes an extract extracted by adding an extractant to a plant and a fraction fractionated by adding a fractional solvent to the extract prepared by extracting with an extractant. Accordingly, the octagonal fennel extract of the present invention is meant to include both the extract extracted by adding a solvent to the octagonal fennel and the fractions fractionated by adding a fractional solvent thereto.

The octagonal fennel extract is water, organic solvent having 1 to 6 carbon atoms or a mixture thereof, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, petroleum ether, subcritical fluid and supercritical It may be extracted with any one or more solvents selected from the group consisting of fluids.

The present invention includes an extraction method of the octagonal fennel extract and an octagonal extract extracted from the extraction method.

In addition, the composition of the present invention includes shikimic acid as an active ingredient.

The "shikimic acid" is a compound extracted or purified from natural products or synthesized, and is represented by the following Chemical Formula 1:

[Formula 1]

The shikimic acid may be derived from octagonal fennel. At this time, it may be prepared by a method of layer separation by adding a solvent to the octagonal fennel extract.

The shikimic acid of the present invention may include hydrates, derivatives, and the like within a range having the same efficacy, and may also include solvent compounds or stereoisomers thereof.

The method for obtaining the shikimic acid is not particularly limited, and a chemically synthesized or commercially available product may be used using a known production method.

In this specification,'muscle' refers to the tendon, muscle, tendon, and'muscle function' refers to the ability to exert power by contraction of the muscle, and the muscle exerts the greatest contractile force to overcome resistance. Includes muscle power, the ability to perform, muscle endurance, the ability to indicate how long or how many times a muscle can repeat contraction and relaxation at a given weight, and wits, the ability to exert strong power in a short period of time. This muscle function is subject to the liver and is proportional to muscle mass. The term'muscle function improvement' refers to improving muscle function better.

In one embodiment of the present invention, it was confirmed that the octagonal fennel extract or shikimic acid, which is an active ingredient according to the present invention, has an excellent ability to increase muscle production from increasing the activity of mTOR in muscle cells.

In addition, in another embodiment of the present invention, the ability to inhibit the degradation of muscle protein from octagonal fennel extract or sickimic acid, which is an active ingredient according to the present invention, reduces mRNA expression of atrogin-1 and MuRF-1 in muscle cells. It was confirmed that it was excellent.

Therefore, in this aspect, the composition of the present invention may be a pharmaceutical composition for preventing and treating muscle disease.

In the present invention, "prophylaxis" refers to all actions that inhibit or delay the onset of the administration of the composition.

In the present invention, "improvement" or "treatment" refers to all actions in which the symptoms of the disease are improved or beneficially altered by administration of the composition.

The composition of the present invention can be used for the prevention or treatment of muscle diseases caused by muscle wasting or degeneration. Muscle wasting and degeneration are caused by genetic factors, acquired factors, aging, and the like, and muscle wasting is characterized by gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or veterinary muscles and cardiac muscles.

In the present invention, muscle diseases due to muscle wasting or degeneration are not limited thereto, but atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia gravis, cachexia, and muscular dystrophy ( sarcopenia), and can be used for the treatment or prevention of various diseases in which natural recovery of muscles is difficult due to these diseases. The composition of the present invention has an effect of increasing muscle mass, and the muscles are not limited in their types.

The pharmaceutical composition of the present invention may include shikimic acid or a pharmaceutically acceptable salt thereof. As used herein, the term “pharmaceutically acceptable” refers to a physiologically acceptable drug that, when administered to a human, typically does not cause an allergic reaction or similar reaction, and the salt is a pharmaceutically acceptable free acid (free). acid) is preferred.

The pharmaceutically acceptable salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, Malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxy acetic acid, benzenesulfonic acid, p- Toluenesulfonic acid or methanesulfonic acid. Inorganic acids include, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid. The acid addition salt may preferably be in the form of a hydrochloride or acetate, more preferably in the form of a hydrochloride.

The above-mentioned acid addition salts are a) general salts that directly mix sickimic acid, or b) dissolve and mix it in a solvent or hydrous solvent, or c) place skimic acid in an acid in a solvent or a water-based solvent and mix them. It is manufactured by the manufacturing method.

Apart from the above, possible salt forms include gaba salt, gabapentin salt, pregabalin salt, nicotinate salt, adipate salt, hemimalonate salt, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt or And aspartates.

In addition, the pharmaceutical composition for preventing and treating muscle diseases of the present invention may further include a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like. In addition, stabilizers and preservatives may be further included. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-parabens and chlorobutanol. As other pharmaceutically acceptable carriers, reference may be made to those described in the following documents (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

The pharmaceutical composition of the present invention can be administered by any method to mammals, including humans. For example, it can be administered orally or parenterally, and the parenteral administration method is not limited thereto, but intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal , Intranasal, intestinal, topical, sublingual or rectal administration.

The pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above. When formulated, one or more buffers (e.g. saline or PBS), antioxidants, bacteriostats, chelating agents (e.g. EDTA or glutathione), fillers, extenders, binders, adjuvants (e.g. aluminum hydroxide) Side), a suspending agent, a thickening agent wetting agent, a disintegrating agent or a surfactant, a diluent or an excipient.

Solid preparations for oral administration include tablets, pills, powders, granules, liquids, gels, syrups, slurries, suspensions or capsules, etc. These solid preparations include at least one excipient in the pharmaceutical composition of the present invention. , Starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, cellulose , Methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl-cellulose or gelatin, and the like. For example, tablets or tablets of sugar can be obtained by blending the active ingredient with a solid excipient and then grinding it and adding a suitable adjuvant to the granule mixture.

In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral use include suspensions, intravenous solutions, emulsions or syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances or preservatives, in addition to water or liquid paraffin, a simple diluent commonly used. .

In addition, if necessary, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant, and may further include an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent, and a preservative. .

When administered parenterally, the pharmaceutical composition of the present invention may be formulated according to methods known in the art in the form of injections, transdermal administrations, and nasal inhalants together with suitable parenteral carriers. The injections must be sterile and protected from contamination of microorganisms such as bacteria and fungi. For injections, examples of suitable carriers include, but are not limited to, solvents or dispersion media comprising water, ethanol, polyols (eg, glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof and/or vegetable oils. Can. More preferably, suitable carriers include Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) with ethanol amine or sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol and 5% dextrose. Etc. can be used. In order to protect the injection from microbial contamination, it may further include various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In addition, the injection may further include isotonic agents such as sugars or sodium chloride in most cases.

In the case of transdermal dosage forms, ointments, creams, lotions, gels, external solutions, pasta agents, linen agents, aerosols, and the like are included. In the above,'dermal administration' means that the pharmaceutical composition is topically administered to the skin to deliver an effective amount of the active ingredient contained in the pharmaceutical composition into the skin.

In the case of inhalation dosages, the compounds used according to the invention may be pressurized packs or, using suitable propellants, such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. It can be conveniently delivered in the form of an aerosol spray from a nebulizer. In the case of pressurized aerosols, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in inhalers or insufflators can be formulated to contain a powder mixture of a compound and a suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975.Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, a prescription generally known to all pharmaceutical chemistries.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention can provide a desirable muscle disease prevention and treatment effect when an octagonal fennel extract or shikimic acid is included in an effective amount. In the present specification, the term'effective amount' refers to an amount that exhibits a higher response than a negative control, and preferably refers to an amount sufficient to improve muscle function. The pharmaceutical composition of the present invention may include octagonal fennel extract or shikimic acid in an amount of 0.01 to 99.99%, and the remaining amount may be occupied by a pharmaceutically acceptable carrier. The effective amount of the octagonal fennel extract or shikimic acid included in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is commercialized.

The total effective amount of the pharmaceutical composition of the present invention can be administered to a patient in a single dose, and can be administered by a fractionated treatment protocol that is administered for a long time in multiple doses. The pharmaceutical composition of the present invention can vary the content of the active ingredient according to the degree of disease. When administered parenterally, it is preferably administered in an amount of 0.01 to 50 mg, more preferably 0.1 to 30 mg per kg of body weight per day based on the octagonal extract or shikimic acid, and when administered orally, the octagonal extract or It may be administered in divided portions of 1 to several times to be administered in an amount of preferably 0.01 to 100 mg, more preferably 0.01 to 10 mg per kg of body weight per day, based on sikimic acid. However, the dose of the octagonal fennel extract or sickimic acid is effective for the patient considering various factors such as the patient's age, weight, health status, sex, disease severity, diet and excretion rate, as well as the administration route and number of treatments of the pharmaceutical composition. Since the dosage is determined, a person having ordinary skill in the art in consideration of this point will be able to determine an appropriate effective dosage according to the specific use of the octagonal extract or shikimic acid for preventing and treating muscle diseases. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration and method of administration as long as it shows the effects of the present invention.

The pharmaceutical composition for preventing and treating muscle diseases of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormonal therapy, chemotherapy, or biological response modifiers.

The composition for preventing and treating muscle diseases or improving muscle function of the present invention may contain octagonal fennel extract or shikimic acid alone. The inclusion of additional components may further enhance the muscle function improving effect of the composition of the present invention. When adding the above components, skin safety, ease of formulation, and stability of active ingredients according to the combined use may be considered.

In another aspect, the pharmaceutical composition of the present invention may be provided as a formulation of an external preparation containing octagonal fennel extract or shikimic acid as an active ingredient.

When the pharmaceutical composition for preventing and treating muscle diseases of the present invention is used as an external preparation for skin, fat substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents ), fragrance, surfactant, water, ionic emulsifier, nonionic emulsifier, filler, metal ion blocker, chelating agent, preservative, vitamin, blocker, wetting agent, essential oil, dye, pigment, hydrophilic active agent, lipophilic active agent Or it may contain an adjuvant commonly used in the field of skin science, such as any other ingredients commonly used in external preparations for skin such as lipid vesicles. In addition, the ingredients may be introduced in an amount commonly used in the field of skin science.

When the pharmaceutical composition for preventing and treating muscle diseases of the present invention is provided as an external preparation for skin, it is not limited thereto, and may be a formulation such as ointment, patch, gel, cream or spray.

In another aspect, the composition of the present invention may be prepared as a food composition for preventing muscle disease or improving muscle function. When the food composition for preventing muscle disease and improving muscle function of the present invention is a food composition, it can be used to prevent or improve muscle disease due to muscle wasting or degeneration. Muscle wasting and degeneration are caused by genetic factors, acquired factors, aging, and the like, and muscle wasting is characterized by gradual loss of muscle mass, weakness and degeneration of muscles, especially skeletal or veterinary muscles and cardiac muscles. Examples of related diseases include atony, muscle atrophy, muscular dystrophy, muscle degeneration, myasthenia gravis, cachexia, and sarcopenia. The composition of the present invention has an effect of increasing muscle mass, and the muscle does not limit its type.

The food composition of the present invention includes all forms of functional foods, nutritional supplements, health foods, food additives and feeds, and includes animals including humans or livestock. Subject to eating. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

Food compositions of this type can be prepared in various forms according to conventional methods known in the art. Beverages (including alcoholic beverages), fruits and processed foods thereof (e.g. canned fruits, bottled foods, jams, marmalades, etc.), fish, meat and processed foods (e.g. ham, sausages) Corn beef, etc.), breads and noodles (e.g. udon, buckwheat noodles, ramen, spagate, macaroni, etc.), juice, various drinks, cookies, syrup, dairy products (e.g. butter, cheese, etc.), edible plant maintenance, margarine , Plant protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.) can be prepared by adding octagonal extract. In addition, it is not limited to the nutritional supplement, but may be prepared by adding octagonal fennel extract to capsules, tablets, pills, and the like. In addition, the health functional food is not limited to this, for example, the octagonal fennel extract itself is prepared in the form of tea, juice, and drink to be consumed by liquefaction, granulation, encapsulation, and powdering for drinking (health drink). Can. In addition, in order to use the octagonal fennel extract as a food additive, it may be prepared and used in the form of a powder or a concentrate. In addition, the octagonal fennel extract can be prepared in the form of a composition by mixing with a known active ingredient known to have an effect of preventing muscle disease and improving muscle function.

When the composition for preventing muscle disease and improving muscle function of the present invention is used as a health drink composition, the health drink composition may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in a conventional beverage. The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 mL of the composition of the present invention, preferably about 0.02 to 0.03 g.

The octagonal fennel extract or shikimic acid may be contained as an active ingredient in a food composition for preventing muscle disease and improving muscle function, but the amount is not particularly limited to an amount effective to achieve an effect for preventing muscle disease and improving muscle function, It is preferred that it is 0.01 to 100% by weight relative to the total weight of the composition. The food composition of the present invention can be prepared by mixing with octagonal fennel extract together with other active ingredients known to be effective in the composition for preventing muscle disease and improving muscle function.

In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acids, alginic acids, salts of alginic acids, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, Glycerin, alcohol or carbonic acid. In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients can be used independently or in combination. The proportion of these additives is not critical, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The food composition of the present invention may be added to a feed additive or feed composition for the purpose of preventing muscle disease or improving muscle function.

In the present invention, the term, "feed additive" is a substance added for the purpose of various effects, such as supplementing nutrients and preventing weight loss, improving digestibility of fiber in feed, improving oil quality, preventing reproductive disorders and improving fertility rates, and preventing high-temperature stress in summer. It includes. The feed additive of the present invention corresponds to the supplementary feed under the feed management method, mineral preparations such as sodium hydrogen carbonate, bentonite, magnesium oxide, and complex minerals, mineral preparations such as zinc, copper, cobalt, and selenium, mineral preparations and kerosene , Vitamin AD, E, nicotinic acid, vitamins such as vitamin B complex, protective amino acids such as methionine and lysine, protective fatty acids such as fatty acid calcium salts, probiotics (lactic acid bacteria), live cultures such as yeast cultures, mold fermentation products, Yeast agents and the like may be further included.

The term "feed" in the present invention, any natural or artificial diet for the animal to eat, eat, digest or suitable for this, or a component of the meal, or the composition of the meal, bone formation promoting composition according to the present invention Feed containing as an active ingredient can be prepared in various forms of feed known in the art, and preferably may include a rich feed, forage and/or special feed, but is not limited thereto.

Thick feed contains seeds, wheat, oats, corn and other grains, and by-products obtained by refining and harvesting grains such as rice bran, wheat bran, barley bran, etc., rice, soybean, fluid, sesame, flaxseed, coco palm, etc. It is a concentrate of fresh liquids obtained from fish, fish meal, fish, fish, and fish residues, such as residual starch, which are the main components of starch residue, which is the remainder of starch residue, which is obtained by subtracting starch from by-products, sweet potatoes, potatoes, etc. Fish Soluble (fish soluble), meat (肉粉), blood, milk powder, skim milk, cheese from milk, whey, which is the balance when manufacturing casein from skim milk, animal feed such as dry whey, yeast, Chlorella and algae, but are not limited thereto.

Forage, silage of raw vegetables such as wild grasses, grasses and greens, roots for feed, beet for feed, and root vegetables such as Luther Bearer, a kind of turnip, raw grass, green grass crops, and grain rooms There are silage, wild grass, hay cut with grass, straw of legumes, and leaves of leguminous plants, which are stored and fermented with lactic acid, but are not limited thereto. Special feeds include mineral feeds such as oyster shells and rock salt, urea feeds such as urea or its derivatives, diureid isobutane, and supplements with ingredients that are not easy to lack when blended with natural feed raw materials. There are, but are not limited to, feed additives and dietary supplements that are added in trace amounts.

The feed additive according to the present invention can be prepared by adding octagonal fennel extract or sickimic acid in an appropriate effective concentration range according to various methods for preparing feeds known in the art.

The feed additive according to the present invention can be applied without limitation as long as it is an object aimed at improving muscle function. For example, it can be applied to any individual such as non-human animals such as monkeys, dogs, cats, rabbits, mormots, rats, mice, cows, sheep, pigs, goats, birds and fish.

In another aspect, the composition for improving muscle function of the present invention may also be a cosmetic composition. The cosmetic composition of the present invention contains an octagonal fennel extract or shikimic acid as an active ingredient, and a basic cosmetic composition (a face wash, cream, essence, cleansing foam and cleansing water-like face wash, pack, and vodioyl) along with dermatologically acceptable excipients. , Color cosmetics composition (foundation, lipstick, mascara, makeup base), hair product composition (shampoo, conditioner, hair conditioner, hair gel) and soap.

The excipients include, but are not limited to, for example, skin emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickening agents and solvents. In addition, fragrances, pigments, fungicides, antioxidants, preservatives and moisturizers may be further included, and for the purpose of improving physical properties, may include thickeners, inorganic salts, synthetic polymer materials, and the like. For example, in the case of preparing the cleanser and soap with the cosmetic composition of the present invention, it can be easily prepared by adding an octagonal extract to a conventional cleanser and soap base. When preparing a cream, it can be prepared by adding an octagonal fennel extract or a salt thereof to a cream base of a general oil-in-water type (O/W). Synthetic or natural materials such as proteins, minerals, vitamins, etc. for the purpose of improving physical properties may be additionally added to fragrances, chelating agents, pigments, antioxidants, preservatives, and the like.

The content of the octagonal fennel extract or shikimic acid contained in the cosmetic composition of the present invention is not limited to this, but is preferably 0.001 to 10% by weight, and more preferably 0.01 to 5% by weight based on the total weight of the total composition.

Hereinafter, the present invention will be described in more detail through examples.

However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following examples.

[Example 1]

Preparation of octagonal fennel extract

<1-1> Preparation of octagonal ethanol extract

After crushing the dried octagonal fennel with a mixer, 10 g of the crushed octagonal sample was added to 100 mL of 10%, 30%, 50%, 70% 100% ethanol, respectively, and extracted repeatedly at 40°C for 3 hours. The extracted sample was filtered under reduced pressure with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent components, and then octagonal fennel 10%, 30%, 50%, 70%, 100% ethanol extract Got

<1-2> Preparation of 50% Ethanol Extract of Octagonal Fennel

50% ethanol mixed with ethanol and water in a weight ratio of 50:50, respectively, was performed in the same manner as in Example <1-1> to obtain an octagonal 50% ethanol extract.

<1-3> Preparation of octagonal fennel hot water extract

Octagonal fennel hot water extract was obtained in the same manner as in Example <1-2> except that water was used and that the process proceeded at 80°C.

<1-4> Preparation of octagonal ethyl acetate extract

It was carried out in the same manner as in Example <1-1> except that ethyl acetate was used to obtain an octagonal ethyl acetate extract.

<1-5> Preparation of octagonal hexane extract

The octagonal hexane extract was obtained in the same manner as in Example <1-1> except that hexane was used.

<1-6> Preparation of octagonal fennel ultra high pressure extract

After crushing the dried octagonal fennel, 76 mL of 18% ethanol was put in a polyethylene pack, sealed, and then extracted using an ultra-high pressure extraction device (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan). The extraction conditions of the ultra-high pressure were 320 MPa and the extraction time was 5 minutes. The extracted sample was filtered with Whatman No. 1 filter paper, and the filtered extract was concentrated with a vacuum rotary concentrator to remove the solvent component to obtain an octagonal fennel ultra-high pressure extract.

<1-7> Preparation of subcritical extract of octagonal fennel

After crushing the dried octagonal fennel, 50 g of the crushed octagonal fennel was placed in a subcritical water reactor of a subcritical extraction apparatus (Biovan, Gyeonggi, Korea) together with 1 L water and sealed. After sealing, the temperature of the reactor was raised to 200°C, and when the temperature of the reactor reached 200°C, heating was stopped, and the temperature was maintained for 20 minutes to extract. After 20 minutes, the extract was transferred to a storage tank supplied with cooling water, rapidly cooled to 30°C, and centrifuged at 3,600 rpm for 30 minutes to separate the floating residue, and only the supernatant was taken. Octagonal fennel subcritical extract was obtained by removing all solvents using a freeze dryer (ilShin Lab Co. Ltd.).

<1-8> Preparation of Supercritical Extract of Octagonal Fennel

After crushing the dried octagonal fennel, 1 g of the crushed octagonal fennel was charged into a sample cartridge and extracted using a supercritical fluid extraction device (SFX 3560, Isco Inc., Lincoln, NE, USA). In the supercritical extraction conditions, the extraction pressure was 400 bar or 200 bar, the extraction temperature was 50°C, the flow rate of supercritical carbon dioxide was 60 mL/min, and the extraction time was 2 hours. When the supercritical fluid extraction was completed, the pressure of the extraction device was lowered to release the supercritical fluid state to obtain an octagonal supercritical extract.

[Example 2]

Confirm the activity of octagonal muscle formation

It is known that when mTOR protein is phosphorylated and activated, it can induce activation of proteins involved in muscle protein synthesis and muscle mass increase in the PI3K/Akt signaling pathway in muscle cells. Thus, in order to confirm the activity of octagonal muscle production, mTOR activity was confirmed using an mTOR Sandwich ELISA kit (Cell Signaling Technology, Beverly, MA, USA).

L6 myoblasts (ATCC; Manassas, VA, USA) in 1-well plates in 6-well plates with Dulbecco's modified Eagle's media (DMEM; Hyclone) with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) After seeding to be 10 ⁵ cells/well, the cells were cultured for 24 hours. After incubation, the medium in the well was removed and exchanged with DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) to further incubate for 6 days to differentiate L6 cells into myotubes. Then, the octagonal fennel 50% ethanol extract (10 μg/mL) prepared in Example 1-2, the octagonal ethanol extract (10 μg/mL), the octagonal hot water extract prepared in 1-5 (10 μg/ mL) was dissolved, treated with cells and incubated for 12 hours. After incubation, cells were lysed by treatment with a cell lysis buffer. The protein in the obtained cell lysate was quantified by the method of Bradford (Bio-Rad Laboratories Inc., Hercules, CA, USA), and then quantified at a concentration of 1 mg/mL for cell use in a microwell attached with an anti-mTOR antibody. The seafood was dispensed in 50 μL increments and cultured at 37° C. for 2 hours. After incubation, washed 4 times with washing buffer, treated with detection antibody, and incubated for 1 hour at 37°C. After washing 4 times with washing buffer solution, mustard-free peroxidase (horseradish peroxidase, HRP) was added to the conjugated secondary antibody was incubated at 37 ℃ for 30 minutes. Finally, after washing a total of 4 times with a washing buffer solution, the TMB substrate was placed in each well, incubated at 37° C. for 10 minutes, and a stop solution was added to stop the reaction of TMB. After 2 minutes, the absorbance was measured at a wavelength of 450 nm to measure the mTOR level in the root canal cells treated with the octagonal hot water extract and the octagonal ethanol extract. The results are shown in FIG. 1.

As a result, as shown in Figure 1, it was confirmed that the activity of mTOR in L6 muscle cells increased as the octagonal fennel hot water extract, octagonal fennel 50% ethanol extract, and octagonal ethanol extract were treated.

This means that the octagonal fennel 50% ethanol extract, octagonal ethanol extract, and octagonal fennel hot water extract of the present invention have excellent ability to increase muscle production in muscle cells.

[Example 3]

Confirmation of effect of promoting mRNA translation activity in muscle cells by octagonal fennel

Muscle cell L6 myoblast (ATCC, Manassas, VA, USA) in a 6-well plate with Dulbecco's modified Eagle's Media (DMEM; Hyclone) with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) 2 x 10 ⁵ cells/mL was added. When the cell density was about 80-85%, the medium in the well was removed and octagonal 50% ethanol prepared in Example 1-2 in DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) After dissolving the extract (10 μg/mL), octagonal ethanol extract (10 μg/mL), and octagonal hot water extract (10 μg/mL) prepared in 1-5, the cells were treated and induced myotube differentiation. At this time, the group treated with 0.01% DMSO instead of the sample was used as a control. After this process was performed for 6 days for 2 days and differentiated, it was dissolved with an NP-40 buffer solution containing proteinase inhibitor cocktail (ELPIS-Biotech, Daejeon, Korea). The cells lysed in the buffer solution were transferred to a 1.5 mL tube and centrifuged at 13,000 rpm for 10 minutes to take only the supernatant. The supernatant was quantified using the method of Bradford (Bradford, Bio-Rad Laboratories Inc., Hercules, CA, USA). The quantified protein was boiled for 5 minutes and then separated by electrophoresis with 10% SDS-PAGE, and the separated proteins were transferred to a nitrocellulose membrane. The p-mTOR primary antibody (Cell signaling technology, Beverly, MA, USA) was diluted in a ratio of 1:1000 in 2.5% bovine serum albumin (BSA) to react with the protein delivered to the nitrocellulose membrane at room temperature for 20 hours. . After reacting the primary antibody, the nitrocellulose membrane was washed three times for 10 minutes using Tris-buffer Saline Tween20 (TBST). After washing, the anti-rabbit secondary antibody (Bethyl Laboratories, Inc., Montgomery, TA, USA) conjugated with horseradish peroxidase recognizing the primary antibody was diluted to 1:5000 in 2.5% BSA with nitrocellulose membrane 2 The mixture was reacted at room temperature for an hour, and washed three times with 10 minutes using TBST. Protein bands were developed using ECL western blotting detection reagents (Amersham, Tokyo, Japan), and protein bands developed using a G;BOX EF imaging system (Syngene, Cambridge, UK) were identified. The results are shown in FIG. 2.

As a result, as shown in FIG. 2, it was confirmed that the expression level of p-mTOR was increased in L6 muscle cells by treatment of octagonal fennel 50% ethanol extract, octagonal ethanol extract, and octagonal fennel hot water extract.

This means that the octagonal fennel 50% ethanol extract, octagonal ethanol extract, and octagonal fennel hot water extract of the present invention have excellent ability to increase muscle production in muscle cells.

[Example 4]

Confirmation of the effect of octane fennel inhibitory activity in muscle cells

The muscle cell L6 myoblast (ATCC) was placed in a 6-well plate with 2% 10 ⁵ cells/mL in DMEM (Hyclone) containing 10% FBS (Hyclone). When the cell density was about 80-85%, the medium in the well was removed and DMEM (Hyclone) containing 2% HS (Hyclone) was treated to the cells to induce myotube differentiation. Differentiation was performed every 6 days for a total of 6 days by replacing with a new medium. After differentiation, octagonal 50% ethanol extract prepared in Example 1-2 in DMEM (Hyclone) containing 50 ng/mL tumor necrosis factor alph (TNF-α; PeproTech, Rocky Hills, NJ, USA) (10 μg/mL), octagonal ethanol extract (10 μg/mL), and octagonal hot water extract (10 μg/mL) prepared in 1-5 were dissolved and treated to cells. After 6 hours, total RNA was isolated using a TRIzol reagent (Invitrogen). Total RNA isolated was quantified using a nanodrop (NanoDrop 1000; Thermo Fisher Scientific Inc.). Quantitative 16 μL of RNA was synthesized by cDNA under conditions of 42°C 55 minutes and 70°C 15 minutes using Reverse Transcriptase Premix (ELPIS-Biotech) and PCR machine (Gene Amp PCR System 2700; Applied Biosystems). 16 μL of the generated cDNA, 1 μL of cDNA, the following specific primer (Bioneer) and PCR premix (ELPIS-Biotech) were repeated 30 times at 95°C for 30 seconds, 60°C for 1 minute, and 72°C for 1 minute. PCR was performed.

Atrogin-1

Forward primer: 5'-GTTACTGCAACAAGGAGAATCTGTT-3' (SEQ ID NO: 1)

Reverse primer: 5'-CCGTATGAGTCTTATGTTTTGCTGG-3' (SEQ ID NO: 2)

MuRF-1

Forward primer: 5'-CCGGACGGAAATGCTATGGA-3' (SEQ ID NO: 3)

Reverse primer: 5'-AGCCTGGAAGATGTCGTTGG-3' (SEQ ID NO: 4)

β-Actin:

Forward primer: 5'-TGACAGGATGCAGAAGGAGATTAC-3' (SEQ ID NO: 5)

Reverse primer: 5'-TAAAACGCAGCTCAGTAACAGTC-3' (SEQ ID NO: 6)

As a result of PCR, the amplified cDNA was separated by electrophoresis with a 1.5% agarose gel, and the cDNA band was confirmed using a G;BOX EF imaging system (Syngene). The results are shown in FIG. 3.

As a result, as shown in FIG. 3, it was found that mRNA expression of atrogin-1 and MuRF-1 in L6 muscle cells was decreased by treatment of octagonal ethanol extract, octagonal ethanol extract, and octagonal hot water extract. .

This means that the octagonal fennel 50% ethanol extract, octagonal ethanol extract, and octagonal fennel hot water extract of the present invention have excellent ability to inhibit muscle protein degradation in muscle cells.

[Example 5]

Confirmation of muscle production activity of octagonal supercritical extract

The octagonal fennel 200 bar supercritical extract and the octagonal fennel 400 bar supercritical extract were tested in the same manner as in Example 2 at concentrations of 20 and 40 μg/mL.

As a result, as shown in FIG. 4, it was confirmed that the activity of mTOR in L6 muscle cells increased as the octagonal 200 bar supercritical extract and the octagonal 400 bar supercritical extract were treated.

This means that the octagonal 200 bar supercritical extract of the present invention and the octagonal 400 bar supercritical extract have excellent ability to increase muscle production in muscle cells.

[Example 6]

Confirmation of the effect of promoting the translational activity of mRNA in muscle cells by sikimic acid

The experiment was carried out in the same manner as in Example 3 above, with the concentration of 1 and 5 μM of sikkim acid.

As a result, as shown in FIG. 5, it was confirmed that the expression level of p-mTOR in L6 muscle cells was increased by treatment with shikimic acid.

This means that the shikimic acid of the present invention has an excellent ability to increase muscle production in muscle cells.

[Example 7]

Confirmation of inhibitory activity of sikimic acid on muscle protein decomposition in muscle cells

The experiment was conducted in the same manner as in Example 4 above, with the concentration of 1 and 5 μM of sickimic acid.

As a result, as shown in Figure 6, it was found that the mRNA expression of atrogin-1 and MuRF-1 in L6 muscle cells was reduced by treatment with sickimic acid.

This means that the shikimic acid of the present invention is excellent in inhibiting muscle protein degradation in muscle cells.

Hereinafter, an example of manufacturing a pharmaceutical, food, or cosmetic product containing the octagonal fennel extract of Example 1 according to the present invention as an active ingredient will be described, but the present invention is intended to be described in detail rather than to limit it. The pharmaceutical, food or cosmetic compositions of Preparation Examples 1 to 3 were prepared according to the following compositional ingredients and composition ratios with the octagonal fennel extract excellent in preventing and treating muscle diseases or improving muscle function.

[Production Example 1] Pharmaceutical

<1-1> powder

After mixing the octagonal fennel extract of Example 1 50 mg, 2 g of crystalline cellulose, a powder was prepared by filling in an airtight fabric according to a conventional powder manufacturing method.

<1-2> tablets

After mixing the octagonal fennel extract of Example 1, 50 mg of crystalline cellulose, and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet manufacturing method.

<1-3> Capsule

Capsules were prepared by mixing 30 mg of octagonal fennel extract of Example 1, 100 mg of whey protein, 400 mg of crystalline cellulose, and 6 mg of magnesium stearate, and then filling into gelatin capsules according to a conventional capsule preparation method.

[Production Example 2] Food

<2-1> Manufacture of healthy food

Octagonal fennel extract of Example 1 above 1000 mg, vitamin A acetate 70 ug, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 ug, vitamin C 10 mg, biotin 10 ug , 1.7 mg nicotinamide, 50 ug folic acid, 0.5 mg calcium pantothenate, 1.75 mg ferrous sulfate, 0.82 mg zinc oxide, 25.3 mg magnesium carbonate, 15 mg potassium phosphate, 55 mg calcium phosphate, 90 mg potassium citrate , 100 mg of calcium carbonate, 24.8 mg of magnesium chloride may be prepared by mixing, and the compounding ratio may be arbitrarily modified, and the above components are mixed according to a conventional health food manufacturing method, and then granules are prepared. It can be used to prepare a health food composition according to a conventional method.

<2-2> Preparation of health drinks

After adding purified water to 1000 g of octagonal fennel extract of Example 1, 1000 mg of citric acid, 100 g of oligosaccharides, 2 g of plum concentrate, and 1 g of taurine, the above ingredients were mixed according to a general method for preparing a healthy beverage of 900 mL, After stirring and heating at 85° C. for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2 L container, sealed and sterilized, and then refrigerated to be used in the manufacture of a health drink composition.

<2-3> Chewing gum

Chewing gum was prepared in a conventional manner by mixing 20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of fragrance, and 2% by weight of water and 0.1% by weight of octagonal extract of Example 1 above.

<2-4> Candy

Candy was prepared by a conventional method by mixing 60% by weight of sugar, 39.8% by weight of starch syrup and 0.1% by weight of fragrance and 0.1% by weight of octagonal extract of Example 1 above.

<2-5> Biscuit

Power 1st class 25.59% by weight, Gravity 1st class 22.22% by weight, 4.80% by weight per white sugar, 0.73% by weight of salt, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonium, 0.17% by weight of sodium bicarbonate, 0.16% by weight of sodium bisulfite , Rice flour 1.45% by weight, vitamin B 0.0001% by weight, milk flavor 0.04% by weight, water 20.6998% by weight, whole milk powder 1.16% by weight, substitute powder 0.29% by weight, calcium phosphate 0.03% by weight, spray salt 0.29% by weight and spray Biscuits were prepared by a conventional method by mixing 7.27% by weight of oil with the weight% of octagonal extract of Example 1 above.

[Production Example 3] Cosmetics

<3-1> Nutrient Cosmetics (Milk Lotion)

The octagonal fennel extract of Example 1 was prepared according to the ratio of the nutrient composition of Table 1, and the nutrient composition was prepared according to a conventional method.

Ingredients Preparation Example 3-1
(weight%) Octagonal fennel extract 2.0 Squalane 5.0 Wax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 1.5 Floating paraffin 0.5 Caprylic/Capric Triglyceride 5.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservatives, pigments, flavors Proper Purified water to 100

<3-2> Flexible Cosmetics (Skin Lotion)

The octagonal fennel extract of Example 1 was prepared according to the ratio of the flexible cosmetic composition of Table 2, and the flexible cosmetic composition was prepared according to a conventional method.

Ingredients Preparation Example 3-2
(weight%) Octagonal fennel extract 2.0 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonylphenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservatives, pigments, flavors Proper Purified water to 100

<3-3> Nutrition Cream

The octagonal fennel extract of Example 1 was prepared according to the nutrient cream formulation ratio of Table 3, and a nutrient cream was prepared according to a conventional method.

Ingredients Preparation Example 3-3
(weight%) Octagonal fennel extract 2.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG60 hardened castor oil 2.0 Floating paraffin 10 Squalane 5.0 Caprylic/Capric Triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 antiseptic Proper Coloring Proper Spices Proper Purified water to 100

<3-4> Massage Cream

Massage cream was prepared according to a conventional method by using the octagonal fennel extract of Example 1 in the proportion of the massage cream formulation shown in Table 4 below.

Ingredients Preparation Example 3-4
(weight%) Octagonal fennel extract 1.0 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Floating paraffin 40.0 Squalane 5.0 Caprylic/Capric Triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservatives, pigments, flavors Proper Purified water to 100

<3-5> Pack

The octagonal fennel extract of Example 1 was prepared according to a conventional method using the pack formulation ratio of Table 5 below.

Ingredients Preparation Example 3-5
(weight%) Octagonal fennel extract 1.0 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonylphenyl ether 0.3 Polysorbate 60 0.3 Preservatives, pigments, flavors Proper Purified water to 100

<3-6> Gel

The octagonal fennel extract of Example 1 was prepared according to a conventional method using the gel formulation ratio of Table 6 below.

Ingredients Preparation Example 3-6
(weight%) Octagonal fennel extract 0.5 Sodium ethylenediamine acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservatives, pigments, flavors Proper Purified water to 100

<110> Industry-Academic Cooperation Foundation, Yonsei University <120> Composition for prevention and treatment of muscular disorder or improvement of muscular functions comprising Illicium verum extract or shikimic acid <130> 1065997 <150> KR 10-2018-0172731 <151> 2018-12-28 <160> 6 <170> KopatentIn 2.0 <210> 1 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for Atrogin-1 <400> 1 gttactgcaa caaggagaat ctgtt 25 <210> 2 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for Atrogin-1 <400> 2 ccgtatgagt cttatgtttt gctgg 25 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Forward primer for MuRF-1 <400> 3 ccggacggaa atgctatgga 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for MuRF-1 <400> 4 agcctggaag atgtcgttgg 20 <210> 5 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for beta-Actin <400> 5 tgacaggatg cagaaggaga ttac 24 <210> 6 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Reverse primer for beta-Actin <400> 6 taaaacgcag ctcagtaaca gtc 23

Claims (17)

Octagonal fennel extract; Or a pharmaceutical composition for preventing or treating muscle diseases containing shikimic acid represented by the following formula (1) as an active ingredient:
[Formula 1]

According to claim 1,
Sikkim acid represented by Formula 1 is a pharmaceutical composition, characterized in that isolated from the octagonal extract.
According to claim 1,
Octagonal fennel extract is a pharmaceutical composition, characterized in that obtained by extracting octagonal fennel with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, subcritical fluid and supercritical fluid.
According to claim 3,
Organic solvents having 1 to 6 carbon atoms include alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride ), Hexane (hexane), cyclohexane (cyclohexane) and petroleum ether (petroleum ether) pharmaceutical composition characterized in that obtained by extracting octagonal fennel with one or more solvents selected from the group consisting of.
According to claim 1,
Octagonal fennel extract is a pharmaceutical composition, characterized in that obtained by extracting octagonal fennel under ultra high pressure conditions of 100 MPa or more.
According to claim 1 to claim 5,
It is characterized by preventing or treating one or more diseases selected from the group consisting of atony, muscle atrophy, muscle dystrophy, muscle degeneration, myasthenia, cachexia and sarcopenia. Pharmaceutical composition.
Octagonal fennel extract; Or a food composition for preventing muscle disease or improving muscle function containing shikimic acid represented by the following formula (1) as an active ingredient:
[Formula 1]

The method of claim 7,
Sikkim acid represented by the formula (1) is a food composition, characterized in that isolated from the octagonal extract.
The method of claim 7,
Octagonal fennel extract is a food composition obtained by extracting octagonal fennel with one or more solvents selected from the group consisting of water, organic solvent having 1 to 6 carbon atoms, subcritical fluid and supercritical fluid.
The method of claim 7,
Organic solvents having 1 to 6 carbon atoms include alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride ), Hexane (hexane), cyclohexane (cyclohexane) and petroleum ether (petroleum ether) at least one solvent selected from the group consisting of octagonal fennel obtained by extracting the food composition.
The method of claim 7,
Octagonal fennel extract is a food composition, characterized in that obtained by extracting octagonal fennel under ultra high pressure conditions of 100 MPa or more.
The method according to claim 7 to 11,
A food composition for preventing one or more diseases selected from the group consisting of atony, muscle atrophy, muscle dystrophy, muscle degeneration, myasthenia, cachexia, and sarcopenia.
Octagonal fennel extract; Or a cosmetic composition for improving muscle function containing shikimic acid represented by the following formula (1) as an active ingredient:
[Formula 1]

The method of claim 13,
Sikkim acid represented by the formula (1) is a cosmetic composition characterized in that separated from the octagonal extract.
The method of claim 13,
Octagonal fennel extract is a cosmetic composition, characterized in that obtained by extracting octagonal fennel with one or more solvents selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, subcritical fluid and supercritical fluid.
The method of claim 13,
Organic solvents having 1 to 6 carbon atoms include alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride ), Hexane (hexane), cyclohexane (cyclohexane) and petroleum ether (petroleum ether) cosmetic composition characterized in that obtained by extracting octagonal fennel with one or more solvents selected from the crowd.
The method of claim 13,
Octagonal fennel extract is a cosmetic composition, characterized in that obtained by extracting octagonal fennel under ultra high pressure conditions of 100 MPa or more.

Images